Estrogen receptor α attenuates therapeutic efficacy of paclitaxel on breast xenograft tumors

Breast Cancer Research and Treatment

Volumn 134, Issue 3, 2012, Pages 969-980

  Chang, Jinjia ^a   Sui, Meihua ^a,b   Fan, Weimin ^a,c  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Breast cancer; Estrogen receptor; Fulvestrant; Paclitaxel; Xenografts

Indexed keywords

ESTROGEN RECEPTOR ALPHA; FULVESTRANT; PACLITAXEL; PROTEIN BCL 2; PROTEIN BCL XL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER RESISTANCE; CELL PROLIFERATION; CHEMOSENSITIZATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BCL-X PROTEIN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, NUDE; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-BCL-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84868204891     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-1994-8     Document Type: Article

References (45)

1. Luck HJ, Roche H (2002) Weekly paclitaxel: an effective and well-tolerated treatment in patients with advanced breast cancer. Crit Rev Oncol Hematol 44(Suppl):S15-S30
2. Ring AE, Ellis PA (2005) Taxanes in the treatment of early breast cancer. Cancer Treat Rev 31(8):618-627. doi:10.1016/j.ctrv. 2005.09.005
3. Kavallaris M, Kuo DY, Burkhart CA, Regl DL, Norris MD, Haber M, Horwitz SB (1997) Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific betatubulin isotypes. J Clin Invest 100(5):1282-1293. doi:10.1172/JCI119642
4. Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang Q, Urbatsch IL, Chang G (2009) Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323(5922):1718-1722. doi:10.1126/science. 1168750
5. Yao X, Hu JF, Li T, Yang Y, Sun Z, Ulaner GA, Vu TH, Hoffman AR (2004) Epigenetic regulation of the taxol resistance-associated gene TRAG-3 in human tumors. Cancer Genet Cytogenet 151(1):1-13. doi:10.1016/j.cancergencyto.2003.08. 021
6. Alli E, Yang JM, Ford JM, Hait WN (2007) Reversal of stathminmediated resistance to paclitaxel and vinblastine in human breast carcinoma cells. Mol Pharmacol 71(5):1233-1240. doi:10.1124/mol.106.029702
7. Maehara Y, Emi Y, Sakaguchi Y, Kusumoto T, Kakeji Y, Kohnoe S, Sugimachi K (1990) Estrogen-receptor-negative breast cancer tissue is chemosensitive in vitro compared with estrogenreceptor-positive tissue. Eur Surg Res 22(1):50-55
8. Sui M, Huang Y, Park BH, Davidson NE, Fan W (2007) Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. Cancer Res 67(11):5337-5344. doi:10.1158/0008-5472. CAN-06-4582
9. Sui M, Chen F, Chen Z, Fan W (2006) Glucocorticoids interfere with therapeutic efficacy of paclitaxel against human breast and ovarian xenograft tumors. Int J Cancer 119(3):712-717. doi:10.1002/ijc.21743
10. Sui M, Jiang D, Hinsch C, Fan W (2010) Fulvestrant (ICI 182, 780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine. Breast Cancer Res Treat 121(2):335-345. doi:10.1007/s10549- 009-0472-4
11. Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, Buchholz T, Meric F, Middleton L, Hortobagyi GN, Gonzalez-Angulo AM (2006) Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24(7):1037-1044. doi:10.1200/JCO.2005.02.6914
12. Fan W, Sui M, Huang Y (2004) Glucocorticoids selectively inhibit paclitaxel-induced apoptosis: mechanisms and its clinical impact. Curr Med Chem 11(4):403-411
13. Huang Y, Fang Y, Wu J, Dziadyk JM, Zhu X, Sui M, Fan W (2004) Regulation of Vinca alkaloid-induced apoptosis by NF-kappaB/IkappaB pathway in human tumor cells. Mol Cancer Ther 3(3):271-277
14. Huang Y, Johnson KR, Norris JS, Fan W (2000) Nuclear factorkappaB/IkappaB signaling pathway may contribute to the mediation of paclitaxel-induced apoptosis in solid tumor cells. Cancer Res 60(16):4426-4432
15. Dittrich C, Jakesz R, Wrba F, Havelec L, Haas O, Spona J, Holzner H, Kolb R, Moser K (1985) The human tumour cloning assay in the management of breast cancer patients. Br J Cancer 52(2):197-203
16. Aho AJ, Maenpaa JU, Kangas L, Soderstrom KO, Auranen AA, Linna M (1985) Subrenal capsule assay in human breast cancer. Response to cytostatic drug combinations and correlation with receptor status. Eur J Cancer Clin Oncol 21(10):1133-1140
17. Kaufmann M, Klinga K, Runnebaum B, Kubli F (1979) Hormone receptors in breast cancer and response to chemotherapy. N Engl J Med 300(18):1052. doi:10.1056/NEJM197905033001813
18. Maehara Y, Anai H, Kusumoto H, Sugimachi K (1987) Poorly differentiated human gastric carcinoma is more sensitive to antitumor drugs than is well differentiated carcinoma. Eur J Surg Oncol 13(3):203-206
19. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, Ingle JN, Cooper MR, Hayes DF, Tkaczuk KH, Fleming G, Holland JF, Duggan DB, Carpenter JT, Frei E 3rd, Schilsky RL, Wood WC, Muss HB, Norton L (2003) Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21(6):976-983
20. Razandi M, Pedram A, Levin ER (2000) Plasma membrane estrogen receptors signal to antiapoptosis in breast cancer. Mol Endocrinol 14(9):1434-1447
21. Dougherty MK, Schumaker LM, Jordan VC, Welshons WV, Curran EM, Ellis MJ, El-Ashry D (2004) Estrogen receptor expression and sensitivity to paclitaxel in breast cancer. Cancer Biol Ther 3(5):460-467
22. Robertson JF (2001) Faslodex (ICI 182, 780), a novel estrogen receptor downregulator-future possibilities in breast cancer. J Steroid Biochem Mol Biol 79 (1-5):209-212
23. Milas L, Hunter NR, Kurdoglu B, Mason KA, Meyn RE, Stephens LC, Peters LJ (1995) Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol. Cancer Chemother Pharmacol 35(4):297-303
24. Herr I, Ucur E, Herzer K, Okouoyo S, Ridder R, Krammer PH, Von Knebel Doeberitz M, Debatin KM (2003) Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas. Cancer Res 63(12):3112-3120
25. Zhu X, Sui M, Fan W (2005) In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel. Anticancer Res 25 (3 B):1953-1962
26. Kerr JF, Winterford CM, Harmon BV (1994) Apoptosis. Its significance in cancer and cancer therapy. Cancer 73(8):2013-2026
27. Saraste A, Pulkki K (2000) Morphologic and biochemical hallmarks of apoptosis. Cardiovasc Res 45(3):528-537
28. Tan PH, Bay BH, Yip G, Selvarajan S, Tan P, Wu J, Lee CH, Li KB (2005) Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death. Mod Pathol 18(3):374-381. doi:10.1038/modpathol.3800254
29. July LV, Beraldi E, So A, Fazli L, Evans K, English JC, Gleave ME (2004) Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Mol Cancer Ther 3(3):223-232
30. Rajan R, Poniecka A, Smith TL, Yang Y, Frye D, Pusztai L, Fiterman DJ, Gal-Gombos E, Whitman G, Rouzier R, Green M, Kuerer H, Buzdar AU, Hortobagyi GN, Symmans WF (2004) Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response. Cancer 100(7):1365-1373. doi:10.1002/cncr.20134
31. Sagol O, Culhaci N, Yorukoglu K, Ozen E, Canda T (2001) Quantification of tumor cellularity and mitotic index in invasive ductal carcinoma of the breast. Anal Quant Cytol Histol 23(1):21-26
32. Dickson RB, Lippman ME (1988) Control of human breast cancer by estrogen, growth factors, and oncogenes. Cancer Treat Res 40:119-165
33. Yamashita H (2008) Current research topics in endocrine therapy for breast cancer. Int J Clin Oncol 13(5):380-383. doi:10.1007/s10147-008-0818-7
34. Subramaniam DS, Isaacs C (2005) Utilizing prognostic and predictive factors in breast cancer. Curr Treat Options Oncol 6(2):147-159
35. Schmid P, Wischnewsky MB, Sezer O, Bohm R, Possinger K (2002) Prediction of response to hormonal treatment in metastatic breast cancer. Oncology 63(4):309-316. doi:66224 [pii]
36. Wang L, Jiang Z, Sui M, Shen J, Xu C, Fan W (2009) The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study. BMC Cancer 9:226. doi:10.1186/1471-2407-9-226
37. Colleoni M, Minchella I, Mazzarol G, Nole F, Peruzzotti G, Rocca A, Viale G, Orlando L, Ferretti G, Curigliano G, Veronesi P, Intra M, Goldhirsch A (2000) Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. Ann Oncol 11(8):1057-1059
38. Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP (2006) Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295(14):1658-1667. doi:10.1001/jama.295.14. 1658
39. Stearns V, Singh B, Tsangaris T, Crawford JG, Novielli A, Ellis MJ, Isaacs C, Pennanen M, Tibery C, Farhad A, Slack R, Hayes DF (2003) A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. Clin Cancer Res 9(1):124-133
40. Hilf R, Feldstein ML, Gibson SL, Savlov ED (1980) The relative importance of estrogen receptor analysis as a prognostic factor for recurrence or response to chemotherapy in women with breast cancer. Cancer 45(8):1993-2000
41. Hilf R, Feldstein ML, Savlov ED, Gibson SL, Seneca B (1980) The lack of relationship between estrogen receptor status and response to chemotherapy. Cancer 46 (12 Suppl):2797-2800
42. Bottini A, Berruti A, Bersiga A, Brizzi MP, Brunelli A, Gorzegno G, Di Marco B, Aguggini S, Bolsi G, Cirillo F, Filippini L, Betri E, Bertoli G, Alquati P, Dogliotti L (2000) p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin Cancer Res 6(7):2751-2758
43. Makris A, Powles TJ, Dowsett M, Osborne CK, Trott PA, Fernando IN, Ashley SE, Ormerod MG, Titley JC, Gregory RK, Allred DC (1997) Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin Cancer Res 3(4):593-600
44. Wu L, Tannock IF (2005) Effect of the selective estrogen receptor modulator arzoxifene on repopulation of hormoneresponsive breast cancer xenografts between courses of chemotherapy. Clin Cancer Res 11(22):8195-8200. doi:10.1158/1078-0432. CCR-05-1258
45. Chen D, Hackl W, Ortmann O, Treeck O (2004) Effects of a combination of exemestane and paclitaxel on human tumor cells in vitro. Anticancer Drugs 15(1):55-61